Home LiteratureArticle Details
PMID: 18838633 Published · ppublish English Journal Article Research Support, N.I.H., Intramural

Altered cerebral gamma-aminobutyric acid type A-benzodiazepine receptor binding in panic disorder determined by [11C]flumazenil positron emission tomography.

Archives of general psychiatry ·Vol. 65 ·No. 10 ·2008-10-00 ·Pages 1166-75

Hasler G, Nugent AC, Carlson PJ, Carson RE, Geraci M, Drevets WC

Abstract

The benzodiazepine (BZD) receptor system has been implicated in the pathophysiologic mechanism of panic disorder (PD) by indirect evidence from pharmacological challenge studies and by direct evidence from single-photon emission computed tomography and positron emission tomography neuroimaging studies. However, the results of previous neuroimaging studies are in disagreement, possibly because of experimental design limitations related to sample size, matching between patients and controls, and confounding medication effects. To compare BZD receptor binding between subjects with PD and healthy control subjects. Cross-sectional study for association. Psychiatric outpatient clinic of the National Institute of Mental Health. Fifteen subjects with PD who were naïve to BZD drug exposure and were not receiving other drug treatment, and 18 healthy controls. Images of BZD receptor binding were acquired using positron emission tomography and flumazenil tagged with carbon 11. The BZD receptor binding potential was assessed by a simplified reference tissue-tracer kinetic model. The BZD receptor binding potential was decreased in multiple areas of the frontal, temporal, and parietal cortices and was increased in the hippocampus/parahippocampal region in subjects with PD vs controls. The most significant decrease was located in the dorsal anterolateral prefrontal cortex (DALPFC); the most significant increase, in the hippocampus/parahippocampal gyrus. These abnormalities were not accounted for by comorbid depression. In subjects with PD, the severity of panic and anxiety symptoms correlated positively with BZD receptor binding in the DALPFC but negatively with binding in the hippocampus/parahippocampal gyrus. These data provide evidence of abnormal BZD-gamma-aminobutyric acid type A receptor binding in PD, suggesting that basal and/or compensatory changes in inhibitory neurotransmission play roles in the pathophysiologic mechanism of PD. They also provide evidence of an impairment of frontal-limbic interaction in the modulation of anxiety responses, consistent with previous functional and structural neuroimaging studies in PD.

MeSH Terms
Adult Brain/diagnostic imaging,physiopathology Brain Mapping Carbon Radioisotopes Cerebral Cortex/diagnostic imaging,physiopathology Comorbidity Depressive Disorder, Major/diagnostic imaging,physiopathology Dominance, Cerebral/physiology Female Flumazenil/pharmacokinetics Gyrus Cinguli/diagnostic imaging,physiopathology Hippocampus/diagnostic imaging,physiopathology Humans Image Processing, Computer-Assisted Magnetic Resonance Imaging Male Middle Aged Panic Disorder/diagnostic imaging,physiopathology Parahippocampal Gyrus/diagnostic imaging,physiopathology Positron-Emission Tomography Receptors, GABA-A/physiology Reference Values Software
Chemicals
Carbon Radioisotopes Receptors, GABA-A Flumazenil
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Hasler Gregor
Department of Psychiatry, University Hospital, Culmannstrasse 8, 8091 Zurich, Switzerland. g.hasler@bluewin.ch
Nugent Allison C
Carlson Paul J
Carson Richard E
Geraci Marilla
Drevets Wayne C
Article Info
Journal
Archives of general psychiatry
Abbr.
Arch Gen Psychiatry
ISSN
1538-3636
Published
2008-10-00
Pages
1166-75
Language
English
Region
United States
NLM ID
0372435
Subset
IM
Grants
Intramural NIH HHS · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com